Why Extracts Are Critical for Therapeutics
October 28th, 2020
Exclusive, Top Story
Many pharmaceuticals are derived from natural sources that have been known to have medicinal properties for years. For example, ephedrine comes from Ephedra sinica and codeine comes from Papaver somniferum. Modern medicine has enhanced these medicinal properties by extracting and synthesizing compounds at far higher concentrations.
Let’s take a look at why extraction is critical for cannabinoid and psychedelic therapeutics, how Pure Extract Technologies Inc. is already capitalizing on cannabinoids, and why it’s well-positioned to expand into psychedelics over time.
Opium has been actively collected from poppy plants since approximately 3400 BCE, making it one of the oldest known medicinal plants. In fact, the ancient Egyptians used opium as a pain reliever and the Romans used opium during surgical procedures. By the 1800s, scientists began extracting morphine, codeine and other useful individual elements.
The War on Drugs eventually forced the medical community to synthesize chemical compounds present in the opium plant to avoid growing and harvesting a Schedule I narcotic. Soon after, the synthesis of plant-based medicines became the norm due to the lower costs, exacting science and unparalleled level of quality control and consistency for patients.
The synthesis of pharmaceutical compounds led to a focus on specific, well-understood parts of natural plant-based medicines. For instance, modern patients take codeine rather than opium to manage pain. These efforts have led to several unintended consequences, such as the opioid dependence that has arisen from higher than natural concentrations of active ingredients.
Cannabis & Mushrooms
There is growing evidence that the so-called entourage effect could play a larger role in efficacy than originally thought. For example, cannabinoid researchers compared the effects of full-spectrum CBD versus CBD isolate in patients with refractory epilepsy and found a far greater improvement at lower doses with less severe adverse effects in full-spectrum CBD.
In 2009, psychedelic researchers found similar benefits when comparing the effects of an extract from Psilocybe argentipes to pure psilocybin on marble-burying behavior in mice—a model used to study OCD behavior. The results of the study showed that the mushroom extract was more effective at the same dose in reducing the behavior than pure psilocybin.
These studies have led many cannabis and psychedelic companies to pursue full-spectrum products that contain a wide range of compounds (e.g. terpenes, flavonoids, cannabinoids, etc.) rather than chemically isolating a single compound. The interactions between these different naturally-occurring elements seem to have an impact on safety and efficacy.
Pure Extracts Fills the Void
Pure Extract Technologies Inc. is an emerging leader in the production of cannabinoid extracts and is well-positioned to enter psychedelics in time. With an EU-GMP compliant facility in Pemberton, British Columbia, the Company produces high-quality, high-purity formulations on a commercial scale that are solvent-free, highly scalable and designed to meet a wide range of requirements.
The Company’s Vitalis CO2 Extraction System produces full-spectrum oil with a capacity of over 100,000 kilograms of biomass per year. In addition to existing white-label and toll processing agreements, the Company is developing its own in-house, “Pure Pulls” brands to capitalize on the growing demand for high-quality cannabinoid, and potentially, mushroom extracts.
Investors may appreciate the Company’s high-margin, recurring revenue business model associated with its white-label and toll processing agreements in addition to its blue-sky in-house brand development. With plans to go public in November, retail investors may have an opportunity to invest in the future of extraction in cannabis, and potentially, mushrooms.
Medicine has evolved from purely plant-based products to extracted compounds to chemical synthesis. While the latter has become commonplace in pharmaceutical development, emerging evidence suggests that the entourage effect could make extraction a compelling therapeutic for the cannabinoid and psychedelic industries.
Pure Extract Technologies Inc. represents a unique opportunity to invest in the extraction side of the cannabis industry, as well as potentially the psychedelics industry in time. For more information, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.